TY - JOUR
T1 - P53 family interactions and yeast
T2 - Together in anticancer therapy
AU - Gomes, Sara
AU - Leão, Mariana
AU - Raimundo, Liliana
AU - Ramos, Helena
AU - Soares, Joana
AU - Saraiva, Lucília
PY - 2016/4
Y1 - 2016/4
N2 - The p53 family proteins are among the most appealing targets for cancer therapy. A deeper understanding of the complex interplay that these proteins establish with murine double minute (MDM)2, MDMX, and mutant p53 could reveal new exciting therapeutic opportunities in cancer treatment. Here, we summarize the most relevant advances in the biology of p53 family protein-protein interactions (PPIs), and the latest pharmacological developments achieved from targeting these interactions. We also highlight the remarkable contributions of yeast-based assays to this research. Collectively, we emphasize promising strategies, based on the inhibition of p53 family PPIs, which have expedited anticancer drug development.
AB - The p53 family proteins are among the most appealing targets for cancer therapy. A deeper understanding of the complex interplay that these proteins establish with murine double minute (MDM)2, MDMX, and mutant p53 could reveal new exciting therapeutic opportunities in cancer treatment. Here, we summarize the most relevant advances in the biology of p53 family protein-protein interactions (PPIs), and the latest pharmacological developments achieved from targeting these interactions. We also highlight the remarkable contributions of yeast-based assays to this research. Collectively, we emphasize promising strategies, based on the inhibition of p53 family PPIs, which have expedited anticancer drug development.
UR - http://www.scopus.com/inward/record.url?scp=84959193537&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2016.02.007
DO - 10.1016/j.drudis.2016.02.007
M3 - Review article
C2 - 26891980
AN - SCOPUS:84959193537
SN - 1359-6446
VL - 21
SP - 616
EP - 624
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 4
ER -
